Wes Streeting criticises ‘shortsighted’ drug firms for rejecting pricing offer | Health policy

Wes Streting intensified his battle with pharmaceutical companies during the price of their products, saying that he would not let the industry rip up British patients or taxpayers by registering for their requests.

On Sunday, the Secretary of Health accused pharmaceutical companies of being “short -sighted” and has undermined their relations with the government after the two parties were not concluded last week.

Streetting moved away from talks with the British pharmaceutical industry association (APPI) Friday after the Industry Group did not accept government proposals on the amount of their income in the next three years.

The dispute focuses on a voluntary plan in which the NHS fixes its budget for brand medicines and companies agree to reimburse the income they make that go beyond this amount.

The regime is designed to prevent the costs of health services which become uncontrollable, but it has been being examined in recent months after it has not proven to be expensive than what pharmaceutical companies have expected.

The absence of agreement leaves the government in a confrontation with drug manufacturers just as it begins its plan at 10 years to reshape the NHS, and only two months after having identified the life sciences as one of the eight high growth industries at the heart of its industrial plans.

Streetting said: “The pharmaceutical industry has registered in the [pricing] deal with the previous government. When it came out more expensive to industry than expected, we have presented an unprecedented offer to provide payment rates for all future years of the program and accelerate growth in the sector – but the OPPI failed to achieve an agreement.

“It was short -sighted and undermined our efforts to work in collaboration.”

He added: “I will not allow Big Pharma to scam our patients or taxpayers. The life sciences are a great British success. We want the NHS not only to have the revolution of life sciences and medical technology, but to drive it. We remain determined to establish fair partnerships with the sector to deliver for our economy and our society.”

The APPI refused to comment. Its managing director, Richard Torbett, said on Friday: “We must achieve a solution that improves patient access to future innovation, allows the sector to achieve its growth potential and does not require that industry reimburses almost three times more of its income than what is required in other European countries.”

The program launched in 2023 places a ceiling on the quantity of NHS can increase its expenses in brand medication each year. Companies then take a discount on the income they make above this ceiling.

During its first convenience, the government provides that pharmaceutical companies would face a reimbursement rate of 15% this year. But the NHS has spent much more than expected for such drugs, leaving the industry facing a discount rate of approximately 23%.

Street had proposed a series of changes to the program which would have made approximately 1 billion pounds sterling cheaper over the next three years. Pharmaceutical companies claim that the savings are overshadowed by the amount they have to restore to the government during this period, that they planned to be around 13.5 billion pounds sterling.

They have warned that they will have to move drug trials and UK jobs unless the ministers undertake to spend the Budget of the NHS on drugs.

Tom Keith-Roach, president of the United Kingdom of Astrazeneca, said that the United Kingdom was “long-term race”. He added: “As an investor in life sciences, it is difficult for me to defend the United Kingdom as a destination of new R&D or manufacturing or clinical trials if it is impossible for me to bring this innovation to patients.”

Johan Kahlström, president of Novartis UK, said that he was “very difficult for the world’s conference rooms to justify investments in the United Kingdom” as a result of the discounts.

Pharmacy and streets are also in journalization on how the National Institute for Clinical Excellence (Nice) judges whether new drugs deserve to be approved for the NHS.

The regulator approves drugs that cost £ 20,000 to £ 30,000 for each additional year of quality life that they generally add for a patient. Pharmacy firms say this is too low given the recent inflation of the cost of advanced drugs, and some warn that they will not launch their new products in the United Kingdom.

Gilead Sciences said this weekend that he would not submit his latest medication against breast cancer for evaluation by Nice, saying that he would not be able to take sufficient profit.

Streetting said: “Nice was created by the last Labor government to offer a better deal for patients and taxpayers. The process is robust and equitable, and balances the cost of treatment against its effectiveness. Any pharmaceutical company offering drugs that should be comfortable to follow this path.”